

How to Cite:

Swetha, G., Govindaraju, L., Jeevanandan, G., Vishwanathaiah, S., & Maganur, P. C. (2022). Prevalence of prescribing antacids in children treated under general anaesthesia: A retrospective cohort study. *International Journal of Health Sciences*, 6(S1), 11298–11308. <https://doi.org/10.53730/ijhs.v6nS1.7772>

Prevalence of prescribing antacids in children treated under general anaesthesia: A retrospective cohort study

G.Swetha

Research Assistant, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India

Lavanya Govindaraju

Senior Lecturer, Department of Pedodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India

Ganesh Jeevanandan

Associate Professor, Department of Pedodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
Corresponding author email: helloganz@gmail.com

Satish Vishwanathaiah

Associate Professor, Department of Preventive Dental Sciences, Division of Pediatric Dentistry, College of Dentistry, Jazan University, Jazan, Saudi Arabia

Prabhadevi C Maganur

Associate Professor, Department of Preventive Dental Sciences, Division of Pediatric Dentistry, College of Dentistry, Jazan University, Jazan, Saudi Arabia

Abstract---Background: There are a few instances of dental problems in children that can't be handled effectively in the clinic and should be treated in the hospital setup under general anesthesia and the patients are prescribed painkillers and antacids as postoperative medications. Children treated under general anesthesia are common in pediatric dentistry but prescription of antacids is not very common. Aim: To find the Prevalence of prescribing antacids in children treated under general anaesthesia. Materials and Methods: The study was done in private dental college and hospitals, Chennai India. Patient records were reviewed and the data of 300 patients between September 2020 and February 2021 were analyzed. Total sample data was 73 and was minimized by inclusion of all available data. Collected

Data were analyzed using SPSS statistical software. Data analysis done using chi-square test and p-value was set as 0.05 as level of significance. Results: According to the findings of this research, Among 73 children treated under General anesthesia, 32% had antacid prescribed, while 68% were not prescribed with antacids .while 11-18 years were the most prescribed with antacids than other groups. Conclusion: 32% of the children treated under general anaesthesia were prescribed antacids. Ranitidine was the most prescribed antacid for children treated under general anesthesia.

Keywords---antacids, children, general anaesthesia, ranitidine, Innovative.

Introduction

There are some dental problems in children that can't be handled effectively in the clinic and should be treated in the hospital setup. Despite any risk to the patient, the potential to give comprehensive dental services to children in a hospital setting using general anaesthesia (GA) is a beneficial choice for paediatric dentists. Majority of children are managed by dentists using behavioural techniques (1). Certain children, however, will not be able to undergo treatment with these techniques (2). Children's dental treatment under general anesthesia (GA) is a form of rehabilitation (3). The body's protective reflexes are disabled in General Anaesthesia, which causes a state of controlled loss of consciousness (4). For almost three decades, the paediatric community has had access to comprehensive dental rehabilitation by GA (5).

Dental GA is sometimes the most practical and cost-effective treatment choice (2,6). GA is used to treat paediatric patients who are very young, or who have physical, behavioural, neurological, or emotional immaturity or inability, or who have severe anxiety and need comprehensive rehabilitation (7–9). These children aren't good candidates for in-office care, but GA is a better option for them (8). The majority of dental GA patients are children who suffer early childhood caries (ECC) (3,7)(10,11).

Under GA, the required procedures are done in a single session in a hospital setting, resulting in efficient and safe care (5,12). Furthermore, GA is one method of ensuring that the child receives effective pain control (8). Another advantage of GA is that it does not require child cooperation as a requirement of treatment (11).

Oral health has a major impact on overall well-being and quality of life. Recent research examined the effect of GA-based dental care on children's quality of life. It is well known that children who receive this care have a marked difference in their quality of life (13,14).

Children may feel confused following surgery and proper care should be taken. Following discharge, parents are advised to provide painkillers (Paracetamol or Ibuprofen) within the first 24 hours (15). A dose can be received as the child

demonstrates clear liquid tolerance along with which antacids are prescribed. Antacids are often used by physicians as other symptom-relieving medicine to relieve the distress involved with the procedure or pain medications (NSAIDs, opioids) (16).

An antacid is a medication used to relieve heartburn, acid reflux, and stomach upset by lowering stomach acidity (17). Antacids have been used to relieve constipation and diarrhea (18). Antacids are over-the-counter medications that are administered by oral route to treat heartburn, a common symptom of gastroesophageal reflux disease, and indigestion (19). It is composed of a variety of chemicals that include calcium, magnesium, and aluminium salts as active compounds which work by neutralising stomach acid and inhibiting the enzyme pepsin, which is a proteolytic enzyme (20). Our team has extensive knowledge and research experience that has translate into high quality publications (21–33)(34–40). The aim of the present study was to find out the prevalence of prescribing antacids in children treated under general anaesthesia in Chennai.

Materials and Method

The retrospective study was conducted in a private dental college, Chennai, India. Ethical approval was obtained from the Institutional review board prior to the start of the study. Data was collected from the records of the children less than 15 years of age who were treated under general anaesthesia between September 2020 and February 2021. A total of 73 children treated under general anesthesia were included in the study. Data was collected with following parameters like age, gender, antacid prescription of children treated under general anaesthesia The collected data was divided into 3 age groups as 0-5, 6-10 and 11-15 years and was analyzed using SPSS statistical software. Data analysis done using chi-square test and p value was set as 0.05 as level of significance.

Result

Among 73 children treated under General anesthesia, 24 had antacid prescribed, while 49 were not prescribed with antacids (Table 1). Also among 73 patients 19 with antacids prescribed and 48 without antacid prescription belong to 0-5 years while 2 with antacids prescribed and 1 without antacid prescription belong to 6-10 years. And 3 with antacids prescribed belong to 11-18 years (figure 1) implying that most children below age 5 are not prescribed with antacids.

With increase in age, the prescription of antacids also increased and was found to be statistically significant ($P=0.016$). Our study also found that ranitidine was the most commonly prescribed antacid followed by pantoprazole (figure 2). Current study says that prevalence of prescription of antacids in children treated under general anaesthesia is 32%.

Table 1
Showing antacid prescription among different age groups

		Antacid		Total
		Antacid prescribed	Antacid not prescribed	
Age	0-5	19	48	67
	6-10	2	1	3
	11-15	3	0	3
Total		24	49	73




Figure 1: Bar graph showing association between Age and Prescribing antacids in children treated under general anaesthesia. X-axis represents the age and the Y Axis represents the children treated under general anaesthesia. Wherein, the blue color represents antacid prescribed and green color represents antacid not

prescribed. Chi Square test was done, p-value :0.016, ($p < 0.05$) hence statistically significant, providing as age increases prescription of antacids increase.




Figure 2: Bar graph showing association between Age and antacids prescribed in children treated under general anaesthesia. X-axis represents the age and the Y Axis represents the children treated under general anaesthesia. Wherein, the blue color represents pantoprazole and green color represents Ranitidine and yellow colour represents none. Chi Square test was done, p-value :0.034, ($p < 0.05$) hence statistically significant, providing ranitidine is the most prescribed antacid in children treated under general anaesthesia.

Discussion

In the present study it was found that antacids were not commonly prescribed to children below 5 years (figure 1). Only 26.03% of children less than 5 years were given antacids. Use of antacids in children is a controversial topic. Though Antacids are commonly used for infantile colic, gastroesophageal reflux, esophagitis, and other peptic conditions (41)(42), it was also found that children

who are given antacids in their 1st year of life are at risk for bone fractures later in life (43). Proton pump inhibitors (PPIs) and histamine H2-receptor agonists (H2RAs) are two widely prescribed antacids that decrease the amount of acid released by cells in the stomach lining (44). Latest findings have shown that patients taking this medication for acid reflux have a higher chance of bone fractures (45). The study by Malchodi et al also observed that children who were given a PPI before the age of one were 23% more prone to have a bone fracture later in life, and those given a PPI and H2RA were 31% more likely. Meanwhile, children who were given the H2RA alone did not have a higher risk of bone fractures later in life (43)(45).

Also, in the paediatric age group, acid suppression drugs are one of the most often used medications. Long-term use of nonabsorbable antacids like aluminum-magnesium hydroxides has been shown to reduce phosphorus absorption in the gastrointestinal tract (46). A well-known complication of impaired renal tubular phosphate reabsorption is hypophosphatemic bone disorder, also known as rickets or osteomalacia(47).

Acid suppressing drugs have also been linked to a higher risk of *C. difficile* infection (CDI) and recurrent CDI (48). The chance of serious infection with *C. difficile* bacteria, a complicated infection that causes severe diarrhoea, is perhaps the most frightening risk of PPI (49). *C. diff* is effectively kept under control by stomach acid. PPIs, on the other hand, hold stomach acid at a level that protects against the bacteria (50). According to Amy Linsky et al, PPIs increase the incidence of chronic *C. diff* infections in hospitalised patients with *C. diff* infections by 42 percent (51). In another study, Trifan et al discovered that patients taking PPIs had a greater chance of contracting *C. diff* when in the hospital than people taking H2RAs or no antacids (52). Acid suppression medicine must be used caution, particularly in those who are at the highest risk of CDI.

However, antacids relieve heartburn by neutralising the stomach acid that induces it. Children with GERD are treated with non-surgical antacids such as Mylanta and Maalox in prescribed doses (53). Since the digestive tract is still growing in babies and children, reflux is normal. Antacids are used as a pre- and post-anesthetic drug (54)(55,56).

In the present study it was also found that ranitidine was most commonly prescribed antacid (figure 2), it is a histamine 2 receptor antagonist (H2RA) that effectively prevents gastric acid secretion at prescription doses, thus raising intragastric pH and reducing the amount of gastric contents required for reflux into the oesophagus. With over 18 million prescriptions written in 2018, it was the 41st most widely used drug in the United States (57)(58). But studies say that 75 mg ranitidine appears to be effective and safe for use in children to control symptoms of gastroesophageal reflux disease (59)(60) and also doesn't show higher risk of bone fracture unlike the other drugs.

In the present study, it was also observed that the prescription of antacids increased with increase in age and was statistically significant. However there was no equal distribution of children between the three age groups. Only 3 children between the ages of 6-10 and 11-15 years were treated under General anesthesia

which is a potential bias.

This is probably the first study of its kind to report data on prevalence of prescription of antacids in children treated under general anesthesia in Chennai, and the findings may be used to further studies. More studies with larger sample size should be conducted to evaluate the prevalence of using antacids in children treated under general anesthesia and also to estimate the benefit risk ratio.

Conclusion

Within the limits of the study, prevalence of prescribing antacids in children treated under general anaesthesia is 32%, with most prescription in 11-15 years old implying increased prescription of antacid as age increases, and Ranitidine is the most prescribed antacid for children treated under general anesthesia. Antacid drugs should be used with precaution in children because they may have adverse side effects. These observations are essential to the general public since they assist paediatricians, family practise doctors, and other professionals who work with young children in making the right decisions about their long-term health and well-being.

Acknowledgements

The authors would like to acknowledge the help supported by the department of pedodontics and information technology of Saveetha Dental College and Hospitals and management for their constant assistance with the research.

Source of Funding

The present study was supported by the following agencies:

- Saveetha Dental College,
- Saveetha Institute Of Medical And Technical Science,
- Saveetha University
- Gajalakshmi Traders

Conflict Of Interest

None declared.

Reference

1. Ramazani N. Different Aspects of General Anesthesia in Pediatric Dentistry: A Review. Iran J Pediatr [Internet]. 2016 Apr [cited 2021 Feb 25];26(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904485/>
2. Sari ME, Ozmen B, Koyuturk AE, Tokay U. A retrospective comparison of dental treatment under general anesthesia on children with and without mental disabilities. Niger J Clin Pract. 2014 May;17(3):361–5.
3. Schroth RJ, Morey B. Providing timely dental treatment for young children under general anesthesia is a government priority. J Can Dent Assoc. 2007 Apr;73(3):241–3.
4. Lee JY, Vann WF Jr, Roberts MW. A cost analysis of treating pediatric dental patients using general anesthesia versus conscious sedation. Anesth Prog. 2001 Summer;48(3):82–8.

5. Lee P-Y, Chou M-Y, Chen Y-L, Chen L-P, Wang C-J, Huang W-H. Comprehensive dental treatment under general anesthesia in healthy and disabled children. *Chang Gung Med J*. 2009 Nov;32(6):636–42.
6. Thikkurissy S, Crawford B, Groner J, Stewart R, Smiley MK. Effect of passive smoke exposure on general anesthesia for pediatric dental patients. *Anesth Prog*. 2012 Winter;59(4):143–6.
7. Cantekin K, Yildirim MD, Delikan E, Cetin S. Postoperative discomfort of dental rehabilitation under general anesthesia. *Pak J Med Sci Q*. 2014 Jul;30(4):784–8.
8. Forsyth AR, Seminario AL, Scott J, Berg J, Ivanova I, Lee H. General anesthesia time for pediatric dental cases. *Pediatr Dent*. 2012 Sep;34(5):129–35.
9. El Batawi HY. Effect of preoperative oral midazolam sedation on separation anxiety and emergence delirium among children undergoing dental treatment under general anesthesia. *J Int Soc Prev Community Dent*. 2015 Mar;5(2):88–94.
10. Characteristics of child dental neglect: a systematic review [Internet]. Vol. 216, *British Dental Journal*. 2014. p. 469–469. Available from: <http://dx.doi.org/10.1038/sj.bdj.2014.326>
11. Jankauskienė B, Virtanen JI, Kubilius R, Narbutaitė J. Treatment under dental general anesthesia among children younger than 6 years in Lithuania. *Medicina*. 2013;49(9):403–8.
12. Cantekin K, Yildirim MD. Postoperative Discomfort of Dental Rehabilitation under General Anesthesia [Internet]. Vol. 30, *Pakistan Journal of Medical Sciences*. 2014. Available from: <http://dx.doi.org/10.12669/pjms.304.4807>
13. Baghdadi ZD. Children's oral health-related quality of life and associated factors: Mid-term changes after dental treatment under general anesthesia [Internet]. *Journal of Clinical and Experimental Dentistry*. 2015. p. e106–13. Available from: <http://dx.doi.org/10.4317/jced.51906>
14. Jankauskiene B, Virtanen JI, Kubilius R, Narbutaite J. Oral health-related quality of life after dental general anaesthesia treatment among children: a follow-up study [Internet]. Vol. 14, *BMC Oral Health*. 2014. Available from: <http://dx.doi.org/10.1186/1472-6831-14-81>
15. Helgadóttir HL. Pain management practices in children after surgery. *J PediatrNurs*. 2000 Oct;15(5):334–40.
16. Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. *Inflammopharmacology*. 2017 Feb 1;25(1):1–9.
17. Internal Clinical Guidelines Team (UK). Dyspepsia and Gastro-Oesophageal Reflux Disease: Investigation and Management of Dyspepsia, Symptoms Suggestive of Gastro-Oesophageal Reflux Disease, or Both. London: National Institute for Health and Care Excellence (UK); 2014.
18. Salisbury BH, Terrell JM. Antacids. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2020.
19. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. *Gastroenterol Clin North Am*. 1990 Sep;19(3):683–712.
20. Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the role of pepsin. *Int J Otolaryngol*. 2012;2012:646901.
21. Subramanyam D, Gurunathan D, Gaayathri R, Vishnu Priya V. Comparative evaluation of salivary malondialdehyde levels as a marker of lipid peroxidation in early childhood caries. *Eur J Dent*. 2018 Jan;12(1):67–70.

22. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJL. Effectiveness of 2% Articaine as an anesthetic agent in children: randomized controlled trial. *Clin Oral Investig*. 2019 Sep;23(9):3543–50.
23. Ramakrishnan M, Dhanalakshmi R, Subramanian EMG. Survival rate of different fixed posterior space maintainers used in Paediatric Dentistry – A systematic review [Internet]. Vol. 31, *The Saudi Dental Journal*. 2019. p. 165–72. Available from: <http://dx.doi.org/10.1016/j.sdentj.2019.02.037>
24. Jeevanandan G, Thomas E. Volumetric analysis of hand, reciprocating and rotary instrumentation techniques in primary molars using spiral computed tomography: An in vitro comparative study. *Eur J Dent*. 2018 Jan;12(1):21–6.
25. Princeton B, Santhakumar P, Prathap L. Awareness on Preventive Measures taken by Health Care Professionals Attending COVID-19 Patients among Dental Students. *Eur J Dent*. 2020 Dec;14(S 01):S105–9.
26. Saravanakumar K, Park S, Mariadoss AVA, Sathiyaseelan A, Veeraraghavan VP, Kim S, et al. Chemical composition, antioxidant, and anti-diabetic activities of ethyl acetate fraction of *Stachys riederi* var. *japonica* (Miq.) in streptozotocin-induced type 2 diabetic mice. *Food Chem Toxicol*. 2021 Jun 26;155:112374.
27. Wei W, Li R, Liu Q, Devanathadesikan Seshadri V, Veeraraghavan VP, Surapaneni KM, et al. Amelioration of oxidative stress, inflammation and tumor promotion by Tin oxide-Sodium alginate-Polyethylene glycol-Allyl isothiocyanate nanocomposites on the 1,2-Dimethylhydrazine induced colon carcinogenesis in rats. *Arabian Journal of Chemistry*. 2021 Aug 1;14(8):103238.
28. Gothandam K, Ganesan VS, Ayyasamy T, Ramalingam S. Antioxidant potential of theaflavin ameliorates the activities of key enzymes of glucose metabolism in high fat diet and streptozotocin - induced diabetic rats. *Redox Rep*. 2019 Dec;24(1):41–50.
29. Su P, Veeraraghavan VP, Krishna Mohan S, Lu W. A ginger derivative, zingerone-a phenolic compound-induces ROS-mediated apoptosis in colon cancer cells (HCT-116). *J Biochem Mol Toxicol*. 2019 Dec;33(12):e22403.
30. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of *Streptococcus mutans*, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: randomized controlled trial [Internet]. Vol. 24, *Clinical Oral Investigations*. 2020. p. 3275–80. Available from: <http://dx.doi.org/10.1007/s00784-020-03204-9>
31. Sekar D, Johnson J, Biruntha M, Lakhmanan G, Gurunathan D, Ross K. Biological and Clinical Relevance of microRNAs in Mitochondrial Diseases/Dysfunctions. *DNA Cell Biol*. 2020 Aug;39(8):1379–84.
32. Velusamy R, Sakthinathan G, Vignesh R, Kumarasamy A, Sathishkumar D, Nithya Priya K, et al. Tribological and thermal characterization of electron beam physical vapor deposited single layer thin film for TBC application. *Surf Topogr: Metrol Prop*. 2021 Jun 24;9(2):025043.
33. Aldhuwayhi S, Mallineni SK, Sakhamuri S, Thakare AA, Mallineni S, Sajja R, et al. Covid-19 Knowledge and Perceptions Among Dental Specialists: A Cross-Sectional Online Questionnaire Survey. *Risk Manag Healthc Policy*. 2021 Jul 7;14:2851–61.

34. Sekar D, Nallaswamy D, Lakshmanan G. Decoding the functional role of long noncoding RNAs (lncRNAs) in hypertension progression. *Hypertens Res*. 2020 Jul;43(7):724–5.
35. Bai L, Li J, Panagal M, M B, Sekar D. Methylation dependent microRNA 1285-5p and sterol carrier proteins 2 in type 2 diabetes mellitus. *Artif Cells NanomedBiotechnol*. 2019 Dec;47(1):3417–22.
36. Sekar D. Circular RNA: a new biomarker for different types of hypertension. *Hypertens Res*. 2019 Nov;42(11):1824–5.
37. Sekar D, Mani P, Biruntha M, Sivagurunathan P, Karthigeyan M. Dissecting the functional role of microRNA 21 in osteosarcoma. *Cancer Gene Ther*. 2019 Jul;26(7-8):179–82.
38. Duraisamy R, Krishnan CS, Ramasubramanian H, Sampathkumar J, Mariappan S, NavarasampattiSivaprakasam A. Compatibility of Nonoriginal Abutments With Implants: Evaluation of Microgap at the Implant-Abutment Interface, With Original and Nonoriginal Abutments. *Implant Dent*. 2019 Jun;28(3):289–95.
39. Parimelazhagan R, Umapathy D, Sivakamasundari IR, Sethupathy S, Ali D, Kunka Mohanram R, et al. Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients. *Biomed Res Int*. 2021 Mar 16;2021:8568926.
40. Syed MH, Gnanakkan A, Pitchiah S. Exploration of acute toxicity, analgesic, anti-inflammatory, and anti-pyretic activities of the black tunicate, *Phallusia nigra* (Savigny, 1816) using mice model. *Environ Sci Pollut Res Int*. 2021 Feb;28(5):5809–21.
41. Shetty AK, Thomas T, Rao J, Vargas A. Rickets and Secondary Craniosynostosis Associated With Long-term Antacid Use in an Infant [Internet]. Vol. 152, *Archives of Pediatrics & Adolescent Medicine*. 1998. Available from: <http://dx.doi.org/10.1001/archpedi.152.12.1243>
42. Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis [Internet]. Vol. 59, *Archives of Disease in Childhood*. 1984. p. 842–7. Available from: <http://dx.doi.org/10.1136/adc.59.9.842>
43. Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early Acid Suppression Therapy Exposure and Fracture in Young Children. *Pediatrics* [Internet]. 2019 Jul;144(1). Available from: <http://dx.doi.org/10.1542/peds.2018-2625>
44. Illueca M, Alemayehu B, Shoetan N, Yang H. Proton pump inhibitor prescribing patterns in newborns and infants. *J PediatrPharmacolTher*. 2014 Oct;19(4):283–7.
45. Thurston DJ. Early acid suppression therapy exposure and fracture in young children [Internet]. Vol. 24, *Evidence-Based Practice*. 2021. p. 8–9. Available from: <http://dx.doi.org/10.1097/ebp.0000000000001169>
46. Fauley GB. ALUMINUM PHOSPHATE IN THE THERAPY OF PEPTIC ULCER [Internet]. Vol. 67, *Archives of Internal Medicine*. 1941. p. 563. Available from: <http://dx.doi.org/10.1001/archinte.1941.00200030093006>
47. Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus-depletion syndrome in man. *N Engl J Med*. 1968 Feb 22;278(8):409–15.
48. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of Gastric Acid Suppression With Recurrent *Clostridium difficile* Infection: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2017 Jun 1;177(6):784–91.

49. Gopee H, Ede C, Wadula J, Muganza A. Risk factors for *Clostridium difficile*-associated diarrhoea in a burns intensive care unit [Internet]. Vol. 5, Burns Open. 2021. p. 1–5. Available from: <http://dx.doi.org/10.1016/j.burnso.2020.11.001>
50. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea [Internet]. Vol. 357, The Lancet. 2001. p. 189–93. Available from: [http://dx.doi.org/10.1016/s0140-6736\(00\)03592-3](http://dx.doi.org/10.1016/s0140-6736(00)03592-3)
51. Linsky A. Proton Pump Inhibitors and Risk for Recurrent *Clostridium difficile* Infection [Internet]. Vol. 170, Archives of Internal Medicine. 2010. p. 772. Available from: <http://dx.doi.org/10.1001/archinternmed.2010.73>
52. Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of *Clostridium difficile* infection: Systematic review and meta-analysis. World J Gastroenterol. 2017 Sep 21;23(35):6500–15.
53. Gastroesophageal Reflux Disease in Infants and Children. In: Gastroesophageal Reflux Disease. CRC Press; 2000. p. 336–94.
54. Furness S, Yap C, Farquhar C, Cheong YC. Pre and post-operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev [Internet]. 2004 [cited 2021 May 16];(3). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003678.pub2/abstract>
55. Macris SG, Levy L. Preanesthetic Medication [Internet]. Vol. 26, Anesthesiology. 1965. p. 256–256. Available from: <http://dx.doi.org/10.1097/00000542-196503000-00047>
56. Sawyer MM. Postanesthetic Care [Internet]. Anesthesia Secrets. 2011. p. 222–8. Available from: <http://dx.doi.org/10.1016/b978-0-323-06524-5.00033-7>
57. Kane SP, Phar, BCPS. The Top 300 of 2021 [Internet]. [cited 2021 May 12]. Available from: <https://clincalc.com/DrugStats/Top300Drugs.aspx>
58. Government of Canada, Health Canada. Health Canada assessing NDMA in ranitidine [Internet]. 2019 [cited 2021 May 12]. Available from: <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php>
59. Pappa, PAPP, WILLIAMS, PAYNE, BUARON, MUSSARI, et al. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn [Internet]. Vol. 13, Alimentary Pharmacology & Therapeutics. 1999. p. 467–73. Available from: <http://dx.doi.org/10.1046/j.1365-2036.1999.00505.x>
60. Orenstein SR, Blumer JL, Faessel HM, McGuire JA, Fung K, Li BUK, et al. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2002 May;16(5):899–907.